Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Taihei OnoSatoshi IgawaTakahiro OzawaMasashi KasajimaMikiko IshiharaYasuhiro HiyoshiSeiichiro KusuharaNoriko NishinaritaTomoya FukuiMasaru KubotaJiichiro SasakiMitsufuji HisashiMasato KatagiriKatsuhiko NaokiPublished in: Thoracic cancer (2019)
The efficacy of osimertinib does not significantly vary relative to body size variables of patients with T790M-positive NSCLC who progress on prior EGFR-TKIs.